Research

  • Access to all necessary nuclear and GMP facilities
  • Nuclear R&D and operational expertise
  • Partnership representing the full expertise and capabilities
Our research focuses on the development of new radiopharmaceutical products, based on the availability of both high potential medical isotopes and dedicated nuclear infrastructure. We aim for products with a high possibility of adding value to nuclear medicine, more specifically for cancer treatment.

Straight to

drag for more
  • Medical isotope in high demand
  • Beta-emitter
  • Independent supply from in-house FIELD-LAB process
More Information
  • High quality
  • Chemotherapeutic compound (cisplatin) with Pt-195m integrated by synthesis
  • For in-human use
  • Chemotherapeutic function unaltered
More Information
  • Single alpha emitting during decay
  • Ideal half-life (~10 hrs.)
  • Reliable supply
More Information

Lead-212

Pb-212 is a medical isotope with great perspective for cancer therapy; the isotope offers maximal efficiency and minimal side effects.

Pb-212 has a half-life of 11 hours: long enough for targeting purposes, short enough and with a single alpha-emission to avoid long term, off-target damage.

Pb-212 production is complex and is difficult to get access to. FIELD-LAB has managed to achieve unlimited availability by developing its own, in-house production process. In addition, FIELD-LAB operates the facilities autonomously making it flexible in assigning resources and using this high potential isotope for R&D purposes.

Read more

Research
Research

Pt-195m CISSPECT

Pt-195m CISSPECT is a promising imaging agent to measure the distribution of cisplatin chemotherapy in the patient. It can possibly be used to predict the effectivity of cisplatin treatment and/or to determine potential toxicity.

The prediction outcome can then serve as input to optimise the individual patient treatment and to determine whether cisplatin treatment is useful. Or if alternatives should be considered, due to expected severe side effects such as kidney failure, loss of hearing, nausea and tiredness.

Lu-177 chloride n.c.a.

Currently, Lu-177 is dominating the clinical pipeline regarding the innovation of radiopharmaceuticals. Researchers have found numerous possible applications for this radio isotope.

We are looking to provide bio pharma and scientific partners with Lu-177 chloride (n.c.a.) and support their pre-clinical and clinical studies in the development of Lu-177 radiopharmaceuticals. These partners can range from (academic) hospitals to commercial start-ups.

Research

Through FIELD-LAB you can...

drag for more

Obtain research batches

Enter essential nuclear research facilities

Design a scalable R&D plan

Reach a renowned clinical audience

Publications

01 December 2021

A decade ago, it was claimed that alpha-emitters are indispensable when it comes to optimisation of strategies for tumour therapy. Over time, this robust statement has become increasingly relevant, which has resulted in research aiming to develop alpha therapy which can be used in the clinic to substantially improve outcomes for cancer patients. This is exactly what healthcare entrepreneur Jan van Bodegom, MD will present at the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit in Berlin between 7 and 9 December 2021.

02 July 2021

In the University of Warwick and King’s College London, the FIELD-LAB of NRG has found its first international partners. Despite the significant barriers created by both the COVID-pandemic and Brexit, researchers and scientists on both sides of the Channel managed to get things started and hope to present exciting new findings in due time. Dr Cinzia Imberti, Sir Henry Wellcome Postdoctoral Fellow, University of Warwick, UK and Nora Klaassen, project manager R&D at Field-Lab, Petten, the Netherlands, shed some light on how this collaboration started and its hopes for the future.

Publications